主任医师，博士生导师，教授中国临床肿瘤学会(CSCO)副理事长兼秘书长CSCO黑色素瘤专家委员会主任委员CSCO肾癌专家委员会副主任委员CSCO免疫治疗专委会副主任委员CSCO尿路上皮癌专委会副主任委员CSCO前列腺癌专委会副主任委员Melanoma World Society (MWS) 副主席长期从事黑色素瘤、肾癌、膀胱癌、前列腺癌等皮肤、泌尿生殖肿瘤的临床和转化医学研究，对于个体化靶向治疗和生物免疫靶向治疗方面积累了丰富的临床经验。重要成果发表…

主任医师，博士生导师，教授

中国临床肿瘤学会(CSCO)副理事长兼秘书长

CSCO黑色素瘤专家委员会主任委员

CSCO肾癌专家委员会副主任委员

CSCO免疫治疗专委会副主任委员

CSCO尿路上皮癌专委会副主任委员

CSCO前列腺癌专委会副主任委员

Melanoma World Society (MWS) 副主席

长期从事黑色素瘤、肾癌、膀胱癌、前列腺癌等皮肤、泌尿生殖肿瘤的临床和转化医学研究，对于个体化靶向治疗和生物免疫靶向治疗方面积累了丰富的临床经验。重要成果发表于J ClinOncol，Blood，Annals of Oncol, Nat Commun, ClinCan Res等重要SCI期刊，累计影响因子500余分，累计引用次数超过2000次。其中4篇文章被引入美国NCCN黑色素瘤、肾癌和头颈部肿瘤诊治指南(全国个人排名并列4)，多次入选ASCO年会口头报告。曾获北京市科技进步奖二等奖，中国抗癌协会科技奖二等奖，中华医学会科技奖三等奖等。

发表论文

1. Si L, Zhang X, Xu Z, Jiang Q, Bu L, Wang X, Mao L, Zhang W, Richie N, Guo J. Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. BMC Cancer. 2018 May 3;18(1):520. IF=3.288

2. Cui C, Zhou L, Lian B, Si L, Sheng X, Chi Z, Kong Y, Wang X, Tang B, Mao L, Li S, Dai J, Yan X, Bai X, Guo J. Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure. Transl Oncol. 2018 Oct;11(5):1155-1159. IF=3.071

3. Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. J Hematol Oncol. 2018 May 22;11(1):69. IF=7.333

4. Yu J, Wu X, Yan J, Yu H, Xu L, Chi Z, Sheng X, Si L, Cui C, Dai J, Ma M, Xu T, Kong Y, Guo J. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. J Hematol Oncol. 2018 Jan 3;11(1):1. IF=7.333

5. Cui C, Lian B, Zhou L, Song X, Zhang X, Wu D, Chi Z, Si L, Sheng X, Kong Y, Tang B, Mao L, Wang X, Li S, Dai J, Yan X, Bai X, Balch CM, Guo J. Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. Ann Surg Oncol. 2018 Aug;25(8):2184-2192. IF=3.857

6. Li S, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Tang B, Yan X, Wang X, Chi Z, Guo J. Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China. Ann Surg Oncol. 2018 Apr;25(4):885-893. IF=3.857

7. Tang H, Kong Y, Si L, Cui C, Sheng X, Chi Z, Dai J, Yu S, Ma M, Wu X, Yu J, Xu T, Yu H, Yan J, Guo J. Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma. Oncol Lett. 2018 Feb;15(2):1839-1844. IF=1.664

8. Sheng X, Cao D, Yuan J, Zhou F, Wei Q, Xie X, Cui C, Chi Z, Si L, Li S, Mao L, Lian B, Tang B, Yan X, Wang X, Kong Y, Dai J, Bai X, Zhou L, Guo J. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. Eur J Cancer. 2018 Sep;100:1-7. IF=7.191

9. Sheng X, Bi F, Ren X, Cheng Y, Wang J, Rosbrook B, Jiang M, Guo J. First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. Future Oncol. 2019 Jan;15(1):53-63. IF=2.279.

10. Sheng X, Yan X, Chi Z, Si L, Cui C, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Wang K, Tang X, Zhou H, Wu H, Feng H, Yao S, Flaherty KT, Guo J. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. J Clin Oncol. 2019 Nov 10;37(32):2987-2999.IF = 28.349。

11. Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019 Jul 18;10(1):3163.IF = 11.878。

12. Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, Yu J, Yin T, Cheng Z, Wu X, Yu H, Dai J, Sheng X, Si L, Cui C, Bai X, Mao L, Lian B, Wang X, Yan X, Li S, Zhou L, Flaherty KT, Guo J, Kong Y. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. Clin Cancer Res. 2019 Nov 1;25(21):6511-6523. IF = 8.911

13. Tang B, Yan X, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Bai X, Wang X, Li S, Zhou L, Yu J, Dai J, Wang K, Hu J, Dong L, Song H, Wu H, Feng H, Yao S, Chi Z, Guo J. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019 Jan 14;12(1):7. IF =8.731

14. Yu S, Dai J, Ma M, Xu T, Kong Y, Cui C, Chi Z, Si L, Tang H, Yang L, Sheng X, Guo J. RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma. Cell Death Dis. 2019 Mar 15;10(4):254. IF =5.959

15. Yu J, Wu X, Yan J, Yu J, Yin T, Dai J, Ma M, Xu T, Yu H, Xu L, Yang L, Cheng Z, Chi Z, Sheng X, Si L, Cui C, Guo J, Kong Y. Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing. J Cancer. 2019 Jan 1;10(2):488-493. IF = 3.182

16. Cui C, Yan X, Liu S, Deitz AC, Si L, Chi Z, et al.. Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study. International Journal of Surgery: Oncology. 2019;4(6):e76. IF =3.158

17. Si L, Zhang X, Shu Y, Pan H, Wu D, Liu J, Lou F, Mao L, Wang X, Wen X, Gu Y, Zhu L, Lan S, Cai X, Diede SJ, Zhou Y, Ge J, Li J, Wu H, Guo J. A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Transl Oncol. 2019 Jun;12(6):828-835. IF =3.138

18. Wang X, Kong Y, Chi Z, Sheng X, Cui C, Mao L, Lian B, Tang B, Yan X, Si L, Guo J. Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients. Thorac Cancer. 2019 Apr;10(4):950-956. IF = 2.524

19. Yan J, Xu L, Yu J, Wu X, Dai J, Xu T, Yu H, Guo J, Kong Y. Prognostic role of NRAS isoforms in Chinese melanoma patients. Melanoma Res. 2019 Jun;29(3):263-269. IF = 2.381

20. Sheng X, Bi F, Ren X, Cheng Y, Wang J, Rosbrook B, Jiang M, Guo J. First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. Future Oncol. 2019 Jan;15(1):53-63. IF = 2.279

21. Yan X, Sheng X, Chi Z, Si L, Cui C, Kong Y, Tang B, Mao L, Wang X, Lian B, Li S, Bai X, Zhou L, Dai J, Yao H, Guo J. Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. J Clin Oncol. 2021 Mar 10;39(8):881-889. IF = 44.544.

22. Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, Song X, Wang W, Dong L, Song H, Wu H, Feng H, Yao S, Qin S, Zhang X, Guo J. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. Clin Cancer Res. 2020 Aug 15;26(16):4250-4259. doi: 10.1158/1078-0432.CCR-19-3922. IF=10.107.

23. Si L, Zhang X, Shin SJ, Fan Y, Lin CC, Kim TM, Dechaphunkul A, Maneechavakajorn J, Wong CS, Ilankumaran P, Lee DY, Gasal E, Li H, Guo J. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. Eur J Cancer. 2020 Aug;135:31-38. IF=7.275

24. Sheng X, Yan X, Chi Z, Cui C, Si L, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Ding L, Mao L, Guo J. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine. 2020 May;55:102755. IF=5.736

25. Yu J, Yu J, Wu X, Guo Q, Yin T, Cheng Z, Dai J, Kong Y, Guo J. The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma. Clin Sci (Lond). 2020 Jan 31;134(2):193-205. IF=5.223

26. Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z, Sheng X, Kong Y, Mao L, Bai X, Tang B, Li S, Zhou L, Cui C, Guo J. The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Front Oncol. 2020 Sep 29;10:546604. IF=4.848

27. Wang ZL, Mao LL, Zhou ZG, Si L, Zhu HT, Chen X, Zhou MJ, Sun YS, Guo J. Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma. Front Oncol. 2020 Aug 25;10:1524. IF=4.848

28. Dai J, Yang L, Xu T, Si L, Cui C, Sheng X, Chi Z, Mao L, Lian B, Tang B, Bai X, Zhou L, Li S, Wang X, Yan X, Kong Y, Guo J. A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma. J Cancer. 2020 Mar 4;11(10):2945-2956. IF=3.565

29. Wang X, Xu W, Chi Z, Si L, Sheng X, Kong Y, Zhou L, Mao L, Lian B, Tang B, Yan X, Bai X, Cui C, Guo J. Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy. Transl Oncol. 2021 Jan;14(1):100949. IF=4.243

30. Tang B, Chi Z, Guo J. Toripalimab for the treatment of melanoma. Expert Opin Biol Ther. 2020 Aug;20(8):863-869. IF=3.224

31. Sheng X, Jin J, He Z, Huang Y, Zhou A, Wang J, Ren X, Ye D, Zhang X, Qin S, Zhou F, Wang B, Guo J. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. BMC Cancer. 2020 Mar 14;20(1):219. IF=3.15

32. Yu J, Xu L, Yan J, Yu J, Wu X, Dai J, Guo J, Kong Y. MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients. Clin Exp Med. 2020 May;20(2):299-311.IF=2.644

33. Bai X, Kim M, Kasumova G, Si L, Tang B, Cui C, Yang X, Wei X, Cohen J, Lawrence D, Freedman C, Fadden R, Rubin K, Sharova T, Frederick D, Flaherty K, Sullivan R, Guo J, Boland G. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. J Immunother Cancer. 2021 Feb;9(2):e002092. (IF=13.751)

34. Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Jan 1;27(1):43-51.IF=10.107. (IF=12.531)

35. Sheng X, Chen H, Hu B, Yao X, Liu Z, Yao X, Guo H, Hu Y, Ji Z, Luo H, Shi B, Liu J, Wu J, Zhou F, He Z, Fan J, Wang W, Feng H, Yao S, Keegan P, Huang Y, Guo J. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. Clin Cancer Res. 2022 Feb 1;28(3):489-497. (IF=12.531)

36. Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson DB, Sullivan RJ, Boland GM. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clin Cancer Res. 2021 Nov 1;27(21):5993-6000. (IF=12.531)

37. Mao L, Dai J, Cao Y, Bai X, Sheng X, Chi Z, Cui C, Kong Y, Zhang Y, Wu L, Wang X, Tang B, Lian B, Yan X, Li S, Zhou L, Wei X, Li C, Qi Z, Si L, Guo J. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer. 2021 May;148:297-306. IF=9.162

38. Tang B, Mo J, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S, Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J, Sheng X. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. Eur J Cancer. 2021 Oct;156:83-92. IF=9.162

39. Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. Front Immunol. 2021 Jun 4;12:680407. IF=7.561

40. Zhou L, Wang X, Chi Z, Sheng X, Kong Y, Mao L, Lian B, Tang B, Yan X, Bai X, Li S, Guo J, Cui C, Si L. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. Front Immunol. 2021 Jul 5;12:691032. IF=7.561

41. Cui C, Xu C, Yang W, Chi Z, Sheng X, Si L, Xie Y, Yu J, Wang S, Yu R, Guo J, Kong Y. Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. NPJ Genom Med. 2021 Feb 4;6(1):7. IF=8.617

42. Mao L, Ding Y, Bai X, Sheng X, Dai J, Chi Z, Cui C, Kong Y, Fan Y, Xu Y, Wang X, Tang B, Lian B, Yan X, Li S, Zhou L, Wei X, Li C, Guo J, Zhang X, Si L. Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Front Oncol. 2021 Aug 24;11:720044. IF=6.244

43. Bai X, Dai J, Li C, Cui C, Mao L, Wei X, Sheng X, Chi Z, Yan X, Tang B, Lian B, Wang X, Zhou L, Li S, Kong Y, Qi Z, Xu H, Duan R, Guo J, Si L. Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-Ad hoc Analyses of Pooled Data From Two Clinical Trials. Front Oncol. 2021 May 20;11:639085. IF=6.244

44. Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z, Sheng X, Kong Y, Mao L, Bai X, Tang B, Li S, Zhou L, Cui C, Guo J. The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Front Oncol. 2020 Sep 29;10:546604. IF=6.244